Bausch + Lomb (BLCO)
(Delayed Data from NYSE)
$14.96 USD
-0.05 (-0.33%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $14.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BLCO 14.96 -0.05(-0.33%)
Will BLCO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BLCO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLCO
Earnings Preview: Alignment Healthcare (ALHC) Q1 Earnings Expected to Decline
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
BLCO: What are Zacks experts saying now?
Zacks Private Portfolio Services
BLCO vs. AVTR: Which Stock Is the Better Value Option?
All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy
BLCO or AVTR: Which Is the Better Value Stock Right Now?
Other News for BLCO
Bausch + Lomb Corporation (BLCO) Receives a Buy from Wells Fargo
Bausch + Lomb Unveils New Daily Astigmatism Lenses
Bausch + Lomb INFUSEĀ® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
Bausch + Lomb launches Infuse for Astigmatism daily disposable contacts in U.S.
Tracking Carl Icahn's 13F Report - Q1 2024 Update